Lilly Reports Solid First-Quart...() Arxxant(TM) (ruboxistaurin mesyla...)

Arxxant(TM) (ruboxistaurin mesylate, Lilly)

Byetta(R) (exenatide injection, Amylin Pharmaceuticals)

Cialis(R) (tadalafil, Lilly)

Comfortis(TM) (Lilly)

Cymbalta(R) (duloxetine hydrochloride, Lilly)

Evista(R) (raloxifene hydrochloride, Lilly)

Forsteo(R) (teriparatide of recombinant DNA origin injection, Lilly)

Forteo(R) (teriparatide of recombinant DNA origin injection, Lilly)

Gemzar(R) (gemcitabine hydrochloride, Lilly)

Humalog(R) (insulin lispro injection of recombinant DNA origin, Lilly)

Humulin(R) (human insulin of recombinant DNA origin, Lilly)

KwikPen(TM) (Lilly)

Strattera(R) (atomoxetine hydrochloride, Lilly)

Symbyax(R) (olanzapine fluoxetine combination, or OFC, Lilly)

Xigris(R) (drotrecogin alfa (activated), Lilly)

Yentreve(R) (duloxetine hydrochloride, Lilly)

Zyprexa(R) (olanzapine, Lilly)

--------------------------------------------

Eli Lilly and Company Employment Information

March 31, 2008 December 31, 2007

-------------- -----------------

Worldwide Employees 40,300 40,600

Eli Lilly and Company

Operating Results (Unaudited) -- REPORTED

(Dollars in millions, except per share data)

Three Months Ended

March 31

2008 2007 % Chg.

--------------------------------

Net sales $ 4,807.6 $ 4,226.1 14 %

Cost of sales 1,111.3 922.5 20 %

Research and development 877.1 834.2 5 %

Marketing, selling and

administrative 1,550.5 1336.8 16 %

Acquired in-process

research and development 87.0 328.5
'/>"/>